regulatory
confidence high
sentiment positive
materiality 0.85
Neurogene's NGN-401 receives FDA Breakthrough Therapy designation for Rett syndrome
Neurogene Inc.
- FDA granted Breakthrough Therapy designation for NGN-401, a gene therapy for Rett syndrome.
- Designation based on interim Phase 1/2 data showing clinically meaningful, durable multidomain improvements.
- Completion of dosing in Embolden registrational trial expected Q2 2026.
- Company plans to present additional interim Phase 1/2 data in mid-2026.
- NGN-401 also has RMAT, Rare Pediatric Disease designations; part of FDA START Pilot Program.